<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169178</url>
  </required_header>
  <id_info>
    <org_study_id>HLX55-001</org_study_id>
    <nct_id>NCT04169178</nct_id>
  </id_info>
  <brief_title>Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status</brief_title>
  <official_title>A Phase 1 Dose Finding/Expansion Study of HLX55, A Monoclonal Antibody Targeting Tyrosine-Protein Kinase MET (C-MET) in Patients With Advanced Solide Tumors Refactory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henlix, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henlix, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety&#xD;
      and the tolerability of HLX55 in patients with advanced solid tumors&#xD;
      overexpressing/Mutation/Amplification cMET after failure of standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label and dose escalation study including dose finding stage and&#xD;
      expansion stage.&#xD;
&#xD;
      In dosing finding stage, the study will precede in two phases, (i) a modified accelerated&#xD;
      titration design 2A (ATD 2A) phase and (ii) a traditional 3+3 dose escalation phase aimed at&#xD;
      exploring the safety and MTD of HLX55. Four dose levels are designed for HLX55 in this stage:&#xD;
      2.5, 5, 15, and 25 mg/kg/3 weeks. The 5 mg/kg/3 weeks will serve as the starting dose.&#xD;
&#xD;
      In the dose-expansion stage, three to five cohorts are planned, and different cohorts will&#xD;
      evaluate the efficacy of HLX55 for potential indications. Maximum 20 patients will be accrued&#xD;
      in each cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose finding stage-safety</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Numbers and percentage of patients with adverse events (AEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose finding stage-MTD or RP2D</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The maximum tolerated dose and recommended phase 2 dose (RP2D) of HLX55.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage-safety</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Numbers and percentage of patients with adverse events (AEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage-efficacy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Disease control rate (DCR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage-efficacy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Overall response rate (ORR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose expansion stage-efficacy</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of response (DOR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose finding stage and dose expansion stage-PK profile</measure>
    <time_frame>Through study completion, up to 2 years.</time_frame>
    <description>PK profile of HLX55 including maximum concentration (Cmax), minimum concentration (Cmin), area under concentration (AUC0-tau), half-life (T1/2), clearance (CL) rate and the volume of distribution at steady state (Vss) at different doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose finding stage and dose expansion stage-serum HGF levels</measure>
    <time_frame>Cycle 1 to 3 (each cycle is 21 days)</time_frame>
    <description>Changes in serum HGF levels before and at different time-points after HLX55 treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose finding stage and dose expansion stage-immunogenicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The presence and percentage of anti-HLX55 antibody-positive patients (immunogenicity) by measurement of anti-HLX55 antibodies in serum.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dose finding stage and dose expansion stage-cMET status</measure>
    <time_frame>up to 3 cycles (each cycle is 21 days)</time_frame>
    <description>Relationship between levels or status of c-MET mutations/overexpression/amplification, EGFR mutation and KRAS mutation</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>HLX55, dose finding stage, advanced solid tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive HLX55 at assign dose level, e.g. 2.5, 5, 15 and 25 mg/kg every three weeks followed by a 21-day DLT observation period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX55, dose expansion stage, gastric cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants diagnosed with gastric cancer with will receive HLX55 in recommended phase 2 dose (RP2D) every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX55, dose expansion stage, NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants diagnosed with non-small cell lung cancer (NSCLC) with will receive HLX55 in RP2D every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX55, dose expansion stage, colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants diagnosed with colorectal cancer (CRC) with will receive HLX55 in RP2D every three weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HLX55, dose expansion stage, other solid cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants diagnosed with other solid cancer with will receive HLX55 in RP2D every three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX55</intervention_name>
    <description>A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)</description>
    <arm_group_label>HLX55, dose expansion stage, NSCLC</arm_group_label>
    <arm_group_label>HLX55, dose expansion stage, colorectal cancer</arm_group_label>
    <arm_group_label>HLX55, dose expansion stage, gastric cancer</arm_group_label>
    <arm_group_label>HLX55, dose expansion stage, other solid cancer</arm_group_label>
    <arm_group_label>HLX55, dose finding stage, advanced solid tumor</arm_group_label>
    <other_name>HLX55 monoclonal antibody for Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eligible patients must be 18-years of age or older (or per local regulations) and ≦75&#xD;
             years of age.&#xD;
&#xD;
          2. For dose finding stage: patients with measurable or evaluable advanced or metastatic&#xD;
             solid tumours who have failed standard therapy or for whom no standard therapy is&#xD;
             available.&#xD;
&#xD;
          3. For dose expansion stage: patients with measurable or evaluable advanced or metastatic&#xD;
             solid tumors with histologically confirmed c-MET mutations (MET exon 14 mutations) or&#xD;
             amplifications (MET/CEP7 ratio ≥ 2.0 or MET ≥ 5.0 copies) or over-expression&#xD;
             (immunohistochemistry [IHC] score ≥ 2+) and have failed standard therapy or for whom&#xD;
             no standard therapy is available. Positive c-MET&#xD;
             mutation/amplification/over-expression results should be available before the subject&#xD;
             can receive HLX55.&#xD;
&#xD;
          4. No prior therapy with MET-targeting biological agents (patients who have received&#xD;
             prior therapy with a MET-targeting tyrosine kinase inhibitor [TKI] is allowed.)&#xD;
&#xD;
          5. Must be able to supply adequate tumor tissue. (Adequate tumor biopsy material means&#xD;
             (1) newly biopsied or archival tissue biopsied within 60 days before the first dosing,&#xD;
             (2) Biopsy materials should be adequate for biomarker analysis (c-MET/Kras/EGFR).&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 at the time of&#xD;
             study entry.&#xD;
&#xD;
          7. Able to provide informed consent.&#xD;
&#xD;
          8. A life expectancy longer than three months.&#xD;
&#xD;
          9. Adequate hematologic functions, as defined by absolute neutrophil counts ≥ 1500/mm3; a&#xD;
             haemoglobin level ≥ 9 gm/dL; a platelet count ≥ 100,000/mm3 and an international&#xD;
             normalized ratio ≤ 1.5.&#xD;
&#xD;
         10. An adequate hepatic function defined by a total bilirubin level ≤ 1.5 x of upper limit&#xD;
             of normal values (ULN); aspartate transaminase (AST) and alanine transaminase (ALT)&#xD;
             levels ≤ 2.5 x of ULN or ≤ 5 x of ULN in known hepatic metastases or with primary&#xD;
             hepatocellular carcinoma.&#xD;
&#xD;
         11. Adequate renal function, as defined by the creatinine clearance rate ≥ 50 mL/minute by&#xD;
             Cockcroft-Gault formula. In patients with extreme body weights (body mass index [BMI]&#xD;
             &lt; 18.5 OR &gt; 30) estimated glomerular filtration rate (eGFR) ≥ 50ml/min calculated by&#xD;
             Modification of Diet in Renal Disease (MDRD) formula is acceptable.&#xD;
&#xD;
         12. Adequate cardiac function defined as left ventricular ejection fraction (LVEF) ≥ 50%&#xD;
             measured by either cardiac echo or multigated acquisition (MUGA) scan.&#xD;
&#xD;
         13. At least 21days from prior cytotoxic chemotherapy, prior therapy with investigational&#xD;
             small molecule agents (or medical device) or radiotherapy, at least 28 days from prior&#xD;
             immunotherapy, biological agents or prior major surgery and at least 14 days from&#xD;
             prior hormonal therapy and minor surgery before infusion of first dose of HLX55.&#xD;
&#xD;
         14. For patients with hepatocellular carcinoma, their Child-Pugh score must be A.&#xD;
&#xD;
         15. Able to be followed up as required by the study protocol.&#xD;
&#xD;
         16. Female participants must have a negative pregnancy test at screening if of&#xD;
             childbearing potential or be of non-childbearing potential.&#xD;
&#xD;
         17. Female participants of childbearing potential and male partners with female partners&#xD;
             of childbearing potential must agree to use 2 adequate barrier methods of&#xD;
             contraception during the study and for at least 180 days after last dose of study&#xD;
             drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who still have ≥ grade 2 toxicities from prior therapies.&#xD;
&#xD;
          2. Concurrent unstable or uncontrolled medical conditions with either of the followings:&#xD;
&#xD;
               -  Active systemic infections requiring intravenous antibiotic use within 1 week;&#xD;
&#xD;
               -  Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic&#xD;
                  blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;&#xD;
&#xD;
               -  Clinically significant arrhythmia requiring anti-arrhythmia therapy, unstable&#xD;
                  angina pectoris, congestive heart failure (class III or IV of New York Heart&#xD;
                  Association [NYHA]) or acute myocardial infarction within 6 months;&#xD;
&#xD;
               -  Uncontrolled diabetes or poor compliance with hypoglycemics defined by glycated&#xD;
                  hemoglobin (HbA1c) ≥ 9.5%;&#xD;
&#xD;
               -  The presence of chronically unhealed wound or ulcers;&#xD;
&#xD;
               -  Uncontrolled hypercalcemia (defined as persistent Ionized (free) Calcium ≥ 6.5&#xD;
                  mg/dl despite appropriate management.)&#xD;
&#xD;
               -  Other chronic diseases, which, in the opinion of the investigator, could&#xD;
                  compromise the safety of the patient or the integrity of the study.&#xD;
&#xD;
          3. Newly-diagnosed or symptomatic brain metastases (patients with a history of brain&#xD;
             metastases must have received definitive surgery or radiotherapy, be clinically&#xD;
             stable, and not taking steroids for brain edema at least 14 days before infusion of&#xD;
             the first dose of HLX55 can be allowed in the study). Anticonvulsants are allowed.&#xD;
&#xD;
          4. Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the&#xD;
             cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 3&#xD;
             years can participate).&#xD;
&#xD;
          5. Known history of human immunodeficiency virus infection (HIV), hepatitis B virus&#xD;
             carrier status (HBV surface antigen positive) and hepatitis C carrier (anti-HCV&#xD;
             antibody positive).&#xD;
&#xD;
          6. The patient is the investigator, sub-investigator or anyone directly involved in the&#xD;
             conduct of the study.&#xD;
&#xD;
          7. History or current evidence of any condition or disease that could confound the&#xD;
             results of the study or, in the opinion of Investigator(s), is not in the best&#xD;
             interest of the patient to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tsu-Yi Chao, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shuang Ho Hospital,Ministry of Health and Welfare, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ching-Liang Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wu-Chou Su, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng Kung University Hospital, Tainan, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chia-Lun Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Municipal Wanfang Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>PeiZhi Lu</last_name>
    <phone>+886-2-792-7927</phone>
    <phone_ext>107</phone_ext>
    <email>plu@henlix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu-Chou Su</last_name>
      <phone>886-6-2353535</phone>
      <phone_ext>4292</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare</name>
      <address>
        <city>Taipei county</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsu-Yi Chao</last_name>
      <phone>886-2-22490088</phone>
      <phone_ext>8878</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Liang Ho</last_name>
      <phone>886-2-8792-7211</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taipei Minicipal Wangfang Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia Lun Chang</last_name>
      <phone>886-2-2930-7930</phone>
      <phone_ext>2545</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

